Phase I study of PM534 to patients with advanced solid tumors

The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN97337444

Enrollment

Registered

2026-05-20

Start date

2026-04-10

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date. Other

Interventions

The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.

Exclusion criteria

Exclusion criteria: The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.

Design outcomes

Primary

Measure	Time frame
The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.	—

Countries

England, Spain, United Kingdom

Contacts

Public ContactPharma Mar S.A. Clinical Development Oncology Unit

clinicaltrials@pharmamar.com+34918466000

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Jun 11, 2026